Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial

Autor: Leproux; University of California, Beckman Laser Institute and Medical Clinic, O'Sullivan TD; University of California, Beckman Laser Institute and Medical Clinic; University of Notre Dame, Department of Electrical Engineering, Cerussi A; University of California, Beckman Laser Institute and Medical Clinic, Durkin A; University of California, Beckman Laser Institute and Medical Clinic, Hill B; University of California, Beckman Laser Institute and Medical Clinic, Hylton N; University of California San Francisco, Department of Radiology, Yodh AG; University of Pennsylvania, Department of Physics and Astronomy, Carp SA; Massachusetts General Hospital, Harvard Medical School, Department of Radiology, Boas D; Massachusetts General Hospital, Harvard Medical School, Department of Radiology, Jiang S; Dartmouth College, Thayer School of Engineering, Paulsen KD; Dartmouth College, Thayer School of Engineering, Pogue B; Dartmouth College, Thayer School of Engineering, Roblyer D; Boston University, Department of Biomedical Engineering, Yang W; University of Texas MD Anderson Cancer Center, Department of Diagnostic Radiology, Tromberg BJ; University of California, Beckman Laser Institute and Medical Clinic
Jazyk: angličtina
Zdroj: Journal of biomedical optics [J Biomed Opt] 2017 Dec 01; Vol. 22 (12), pp. 121604. Date of Electronic Publication: 2017 Aug 17.
DOI: 10.1117/1.JBO.22.12.121604
Abstrakt: We present a framework for characterizing the performance of an experimental imaging technology, diffuse optical spectroscopic imaging (DOSI), in a 2-year multicenter American College of Radiology Imaging Network (ACRIN) breast cancer study (ACRIN-6691). DOSI instruments combine broadband frequency-domain photon migration with time-independent near-infrared (650 to 1000 nm) spectroscopy to measure tissue absorption and reduced scattering spectra and tissue hemoglobin, water, and lipid composition. The goal of ACRIN-6691 was to test the effectiveness of optically derived imaging endpoints in predicting the final pathologic response of neoadjuvant chemotherapy (NAC). Sixty patients were enrolled over a 2-year period at participating sites and received multiple DOSI scans prior to and during 3- to 6-month NAC. The impact of three sources of error on accuracy and precision, including different operators, instruments, and calibration standards, was evaluated using a broadband reflectance standard and two different solid tissue-simulating optical phantoms. Instruments showed <0.0010 mm−1 (10.3%) and 0.06 mm−1 (4.7%) deviation in broadband absorption and reduced scattering, respectively, over the 2-year duration of ACRIN-6691. These variations establish a useful performance criterion for assessing instrument stability. The proposed procedures and tests are not limited to DOSI; rather, they are intended to provide methods to characterize performance of any instrument used in translational optical imaging.
Databáze: MEDLINE